Praxbind, specific reversal agent for Pradaxa, available nationwide
Boehringer Ingelheim announced that Praxbind (idarucizumab), a specific reversal agent for Pradaxa (dabigatran etexilate mesylate), is now stocked in 3,200 hospitals in all 50 states.